About VASCULAR BIOSCIENCES
Vascular BioSciences (VBS) is a company focused on developing interventional catheters, molecular diagnostic solutions, and targeted therapies for serious vascular-based diseases. Their lead therapeutic candidate, CAR peptide, is being developed for the treatment of pulmonary hypertension, sepsis, and COVID-19.
Development of CAR peptide technology for targeted therapeutic deliveryProduction of the Endoarterial Biopsy Catheter for minimally invasive vascular biopsiesMolecular diagnostics for vascular disease analysisResearch and development of therapies for pulmonary hypertension, sepsis, and other critical care applications
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to VASCULAR BIOSCIENCES right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.